{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,4,23]],"date-time":"2023-04-23T19:52:47Z","timestamp":1682279567931},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","europeanneuropsychopharmacology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.euroneuro.2018.01.008","type":"journal-article","created":{"date-parts":[[2018,2,10]],"date-time":"2018-02-10T05:10:33Z","timestamp":1518239433000},"page":"361-368","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Glycogen synthase kinase-3\u03b2 activity and cognitive functioning in patients with bipolar I disorder"],"prefix":"10.1016","volume":"28","author":[{"given":"Klaus","family":"Munkholm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamilla Woznica","family":"Miskowiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Sophie","family":"Jacoby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maj","family":"Vinberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leda","family":"Leme Talib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wagner Farid","family":"Gattaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars Vedel","family":"Kessing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 2","key":"10.1016\/j.euroneuro.2018.01.008_bib1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/bdi.12341","article-title":"A review on the impact of cognitive dysfunction on social, occupational, and general functional outcomes in bipolar disorder","volume":"17","author":"Baune","year":"2015","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.euroneuro.2018.01.008_bib2","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1176\/appi.ajp.2012.12070908","article-title":"Association of GSK-3beta genetic variation with GSK-3beta expression, prefrontal cortical thickness, prefrontal physiology, and schizophrenia","volume":"170","author":"Blasi","year":"2013","journal-title":"Am. J Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.01.008_bib3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrn3475","article-title":"Power failure: why small sample size undermines the reliability of neuroscience","volume":"14","author":"Button","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.euroneuro.2018.01.008_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13854049308401883","article-title":"Psychological examination of traumatic encephalopathy","volume":"7","author":"Corwin","year":"1993","journal-title":"Clin. Neuropsychol."},{"key":"10.1016\/j.euroneuro.2018.01.008_bib5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jad.2016.06.063","article-title":"Prevalence and correlates of cognitive impairment in euthymic adults with bipolar disorder: a systematic review","volume":"205","author":"Cullen","year":"2016","journal-title":"J Affect. Disord."},{"key":"10.1016\/j.euroneuro.2018.01.008_bib6","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3109\/15622975.2010.551408","article-title":"Platelet GSK3B activity in patients with late-life depression: marker of depressive episode severity and cognitive impairment?","volume":"12","author":"Diniz","year":"2011","journal-title":"World J. Biol. Psychiatry: Off. J. World Fed. Soc. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.01.008_bib7","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/bcpt.12637","article-title":"Antinociceptive and Anti-Inflammatory Effects of Ketamine and the Relationship to Its Antidepressant Action and GSK3 Inhibition","volume":"119","author":"do Vale","year":"2016","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.euroneuro.2018.01.008_bib8","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jpsychires.2010.06.002","article-title":"Increased platelet GSK3B activity in patients with mild cognitive impairment and Alzheimer's disease","volume":"45","author":"Forlenza","year":"2011","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2018.01.008_bib9","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/iub.187","article-title":"GSK-3: a key player in neurodegeneration and memory","volume":"61","author":"Giese","year":"2009","journal-title":"IUBMB Life"},{"key":"10.1016\/j.euroneuro.2018.01.008_bib10","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.2044-8260.1967.tb00530.x","article-title":"Development of a rating scale for primary depressive illness","volume":"6","author":"Hamilton","year":"1967","journal-title":"Br. J. Social Clin. Psychol."},{"key":"10.1016\/j.euroneuro.2018.01.008_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neulet.2004.10.031","article-title":"Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease","volume":"373","author":"Hye","year":"2005","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.euroneuro.2018.01.008_bib12","doi-asserted-by":"crossref","first-page":"e867","DOI":"10.1038\/tp.2016.141","article-title":"Increased DNA and RNA damage by oxidation in patients with bipolar I disorder","volume":"6","author":"Jacoby","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.01.008_bib13","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.euroneuro.2014.01.005","article-title":"Association between GSK3beta gene and increased impulsivity in bipolar disorder","volume":"24","author":"Jimenez","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2018.01.008_bib14","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.euroneuro.2013.01.007","article-title":"Genetic variability at IMPA2, INPP1 and GSK3beta increases the risk of suicidal behavior in bipolar patients","volume":"23","author":"Jimenez","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2018.01.008_bib15","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.3233\/JAD-142025","article-title":"Genetic variants of GSK3B are associated with biomarkers for Alzheimer's disease and cognitive function","volume":"44","author":"Kettunen","year":"2015","journal-title":"J. Alzheimer's Dis.: JAD"},{"key":"10.1016\/j.euroneuro.2018.01.008_bib16","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.biopsych.2006.02.027","article-title":"Lithium regulates glycogen synthase kinase-3beta in human peripheral blood mononuclear cells: implication in the treatment of bipolar disorder","volume":"61","author":"Li","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.01.008_bib17","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40263-013-0039-0","article-title":"Potential mechanisms of action of lithium in bipolar disorder. Current understanding","volume":"27","author":"Malhi","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2018.01.008_bib18","doi-asserted-by":"crossref","DOI":"10.1111\/bdi.12534","article-title":"Methodological recommendations for cognition trials in bipolar disorder by the International Society for Bipolar Disorders Targeting Cognition Task Force","author":"Miskowiak","year":"2017","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.euroneuro.2018.01.008_bib19","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/acps.12649","article-title":"Predictors of the discrepancy between objective and subjective cognition in bipolar disorder: a novel methodology","volume":"134","author":"Miskowiak","year":"2016","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2018.01.008_bib20","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000444489","article-title":"Glycogen synthase kinase-3beta: variation over time and the possible association with mood and cognition in healthy individuals","volume":"73","author":"Munkholm","year":"2016","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.euroneuro.2018.01.008_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40263-014-0213-z","article-title":"Glycogen synthase kinase-3 as a therapeutic target for cognitive dysfunction in neuropsychiatric disorders","volume":"29","author":"O'Leary","year":"2015","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2018.01.008_bib22","series-title":"RBANS Manual: Repeatable Battery for the Assessment of Neuropsychological Status","author":"Randolph","year":"1998"},{"key":"10.1016\/j.euroneuro.2018.01.008_bib23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000314311","article-title":"Pharmacogenetics of lithium long-term treatment: focus on initiation and adaptation mechanisms","volume":"62","author":"Serretti","year":"2010","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.euroneuro.2018.01.008_bib24","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.2174\/092986709788186101","article-title":"Lithium pharmacodynamics and pharmacogenetics: focus on inositol mono phosphatase (IMPase), inositol poliphosphatase (IPPase) and glycogen sinthase kinase 3 beta (GSK-3 beta)","volume":"16","author":"Serretti","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.euroneuro.2018.01.008_bib25","series-title":"Army Individual Test Battery: Manual of Directions and Scoring","author":"War Department","year":"1944"},{"key":"10.1016\/j.euroneuro.2018.01.008_bib26","series-title":"Wechsler Adult Intelligence Scale-III","author":"Wechsler","year":"1997"},{"key":"10.1016\/j.euroneuro.2018.01.008_bib27","series-title":"The ICD-10 Classification of Mental and Behavioural Disorders. Clinical Descriptions and Diagnostic Guidelines","author":"WHO","year":"1992"},{"key":"10.1016\/j.euroneuro.2018.01.008_bib28","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archpsyc.1990.01810180089012","article-title":"SCAN. Schedules for Clinical Assessment in Neuropsychiatry","volume":"47","author":"Wing","year":"1990","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.01.008_bib29","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1002\/j.1460-2075.1990.tb07419.x","article-title":"Molecular cloning and expression of glycogen synthase kinase-3\/factor A","volume":"9","author":"Woodgett","year":"1990","journal-title":"EMBO J"},{"key":"10.1016\/j.euroneuro.2018.01.008_bib30","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2174\/1568008033340153","article-title":"Physiological roles of glycogen synthase kinase-3: potential as a therapeutic target for diabetes and other disorders","volume":"3","author":"Woodgett","year":"2003","journal-title":"Curr. Drug Targets Immune, Endocr. Metab. Disord."},{"key":"10.1016\/j.euroneuro.2018.01.008_bib31","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity and sensitivity","volume":"133","author":"Young","year":"1978","journal-title":"Br. J Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.01.008_bib32","first-page":"8124501","article-title":"Valproic acid protects primary dopamine neurons from MPP(+)-induced neurotoxicity: involvement of GSK3beta phosphorylation by Akt and ERK through the mitochondrial intrinsic apoptotic pathway","volume":"2017","author":"Zhang","year":"2017","journal-title":"Biomed. Res Int."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X18300282?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X18300282?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T19:25:53Z","timestamp":1570735553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X18300282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0924977X18300282"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2018.01.008","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glycogen synthase kinase-3\u03b2 activity and cognitive functioning in patients with bipolar I disorder","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2018.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}